MA40875B1 - 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux - Google Patents
2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreuxInfo
- Publication number
- MA40875B1 MA40875B1 MA40875A MA40875A MA40875B1 MA 40875 B1 MA40875 B1 MA 40875B1 MA 40875 A MA40875 A MA 40875A MA 40875 A MA40875 A MA 40875A MA 40875 B1 MA40875 B1 MA 40875B1
- Authority
- MA
- Morocco
- Prior art keywords
- diamino
- quinoline
- substituted
- anticancer agents
- new anticancer
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- NKXSJFUIFJMXED-UHFFFAOYSA-N quinoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=CC(N)=C21 NKXSJFUIFJMXED-UHFFFAOYSA-N 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne de nouveaux dérivés de 2-amino primaire-4-amino secondaire-quinoléine, leur fabrication, des compositions pharmaceutiques les comprenant et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utiles pour le traitement et la prévention de maladies prolifératives néoplasiques et non néoplasiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073325P | 2014-10-31 | 2014-10-31 | |
| EP15837091.6A EP3212629B1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
| PCT/IB2015/002438 WO2016067112A1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40875A MA40875A (fr) | 2017-09-06 |
| MA40875B1 true MA40875B1 (fr) | 2019-01-31 |
Family
ID=55404745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40875A MA40875B1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10722505B2 (fr) |
| EP (1) | EP3212629B1 (fr) |
| JP (1) | JP6588546B2 (fr) |
| KR (1) | KR102548547B1 (fr) |
| CN (1) | CN107148416B (fr) |
| AU (1) | AU2015338844B2 (fr) |
| CA (1) | CA2965262C (fr) |
| CL (1) | CL2017001073A1 (fr) |
| CO (1) | CO2017007325A2 (fr) |
| CR (1) | CR20170177A (fr) |
| CY (1) | CY1121326T1 (fr) |
| DK (1) | DK3212629T3 (fr) |
| DO (1) | DOP2017000107A (fr) |
| EA (1) | EA037119B1 (fr) |
| EC (1) | ECSP17026748A (fr) |
| ES (1) | ES2707125T3 (fr) |
| GE (1) | GEP20207108B (fr) |
| HR (1) | HRP20190107T1 (fr) |
| IL (1) | IL251775B (fr) |
| LT (1) | LT3212629T (fr) |
| MA (1) | MA40875B1 (fr) |
| MY (1) | MY193740A (fr) |
| NI (1) | NI201700052A (fr) |
| PE (1) | PE20191142A1 (fr) |
| PH (1) | PH12017500810A1 (fr) |
| PL (1) | PL3212629T3 (fr) |
| PT (1) | PT3212629T (fr) |
| RS (1) | RS58328B1 (fr) |
| SG (1) | SG11201703479SA (fr) |
| SI (1) | SI3212629T1 (fr) |
| TN (1) | TN2017000168A1 (fr) |
| TR (1) | TR201900148T4 (fr) |
| UA (1) | UA122062C2 (fr) |
| WO (1) | WO2016067112A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2849560T3 (es) * | 2016-05-04 | 2021-08-19 | Genoscience Pharma Sas | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| EP3620164A1 (fr) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd) |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| TW202214245A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 雙非癌藥物用於製備治療癌症之醫藥組合物的用途 |
| CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
| CN112876673B (zh) * | 2021-01-25 | 2021-12-24 | 山东大学 | 一种pH响应性纳米共聚物载体及其制备方法和应用 |
| EP4349336A1 (fr) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combinaison de composés 2,4-diamino-quinoléine substitués et d'inhibiteurs de mek pour une utilisation dans le traitement de cancers du foie |
| EP4520396A1 (fr) | 2023-09-05 | 2025-03-12 | Genoscience Pharma | Forme cristalline de base libre de la 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopipéridin-1-yl)-quinoléine et ses utilisations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| WO2004080463A1 (fr) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese |
| TW201932456A (zh) * | 2013-01-15 | 2019-08-16 | 美商英塞特控股公司 | 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| CN105102442B (zh) * | 2013-03-18 | 2018-11-09 | 基因科学医药公司 | 作为抗癌药的喹啉衍生物 |
-
2015
- 2015-10-26 HR HRP20190107TT patent/HRP20190107T1/hr unknown
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 CA CA2965262A patent/CA2965262C/fr active Active
- 2015-10-26 SI SI201530566T patent/SI3212629T1/sl unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/fr active Active
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/tr unknown
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
- 2015-10-26 MA MA40875A patent/MA40875B1/fr unknown
- 2015-10-26 PL PL15837091T patent/PL3212629T3/pl unknown
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/lt unknown
- 2015-10-26 EA EA201790949A patent/EA037119B1/ru unknown
- 2015-10-26 PT PT15837091T patent/PT3212629T/pt unknown
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/fr not_active Ceased
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
- 2015-10-26 UA UAA201705278A patent/UA122062C2/uk unknown
- 2015-10-26 RS RS20190110A patent/RS58328B1/sr unknown
- 2015-10-26 ES ES15837091T patent/ES2707125T3/es active Active
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/zh active Active
- 2015-10-26 CR CR20170177A patent/CR20170177A/es unknown
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/ja active Active
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/ko active Active
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/es unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/es unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/es unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/es unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/es unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/es unknown
-
2019
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| NZ710854A (en) | Quinolines derivatives as novel anticancer agents | |
| EA201892666A1 (ru) | 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды | |
| MY196327A (en) | New Anthelmintic Quinoline-3-Carboxamide Derivative | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| MX2020001403A (es) | Nuevos derivados de quinolina. | |
| EA201792047A1 (ru) | Новые соединения | |
| CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| MX392259B (es) | ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a | |
| MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MY201535A (en) | Therapeutic compounds | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| JOP20190183B1 (ar) | معدِلات مستقبلات الاستروجين | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives |